Hope thrives in the desert

Available Clinical Trials

The Nevada Cancer Institute offers many diverse options for the treatment of cancer. For more detailed description of each trial, click on the type of cancer to open a PDF document with the details, including criteria for enrollment, for selected study.

Phase 1

Advanced Solid Malignancies Phase I/IIDianna
(702)822-5483
A Phase I/II, multi-center, open label study of BEZ235, administered orally on a continuous daily dosing schedule in adult patient with advanced solid malignancies including patients with advanced breast cancer
Advanced Solid Malignancies Phase ISandy
(702)822-5174
A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer
Refractory or Metastatic Tumors Phase ISandy
(702)822-5174
A Phase I Study of EC0225 Administered Weeks 1 & 2 of a 4 Week Cycle
Advanced Solid Tumors Phase ITherica
(702)822-5293
An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 with AMG 706, AMG 386 with Bevacizumab, AMG 386 with Sorafenib, and AMG 386 with Sunitinib in Adult Patients with Advanced Solid Tumors
Advanced Solid Malignancies Phase I/IIDianna
(702)822-5483
A phase I/II, multi-center, open-label study of BGT226, administered orally in adult patients with advanced solid malignancies including patients with advanced breast cancer
Adult Cancer Patients Phase IDianna
(702)822-5483
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Advanced Solid Tumors & Malignant Pleural Mesothelioma Phase I/IIDianna
(702)822-5483
Phase I/II study of a triplet combination of CBP501, pemetrexed and cisplatin in patients with advanced solid tumors and in chemotherapy-naïve patients with malignant pleural mesothelioma
Metastatic Cancer Phase IAnnette
(702)822-5177
Inhibition of DNA Methylation by 1-hr Infusion of 5-aza-2'-deoxycitidine (Decitabine) x 10 Days (M-F) with Escalating Doses of SC Pegylated (PEG) Interferon-alfa 2B: A Phase I Study with Molecular Correlates
Refractory or Relapsed Cancer Phase IAnnette
(702)822-5177
Phase 1 Study of MPC-3100 in Patients with Refractory or Relapsed Cancer

Gastrointestinal

GI cancers Phase I/IIKaren
(702)822-5367
A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combinations with chemotherapy and bevacizumab in patients with metastatic colorectal cancer preceded by a phase 1 portion

Genitourinary

Prostate Cancer Phase IIICarol
(702)822-5449
A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT by Chemotherapy With Docetaxel and Prednisone For Localized, High-Risk Prostate Cancer
Prostate Cancer Phase IbLorene
(702)822-5282
An open label, single arm, Phase Ib dose finding study of i.v. panobinostat (LBH589) with docetaxel & prednisone in patients with hormone refractory prostate cancer
Detection of Clear Cell Renal Cell CarcinomaPhase IIIJacky
(702)822-5393
A Comparative Study of PET/CT vs. Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients with Renal Masses Using Iodine-124 labeled Chimeric G250 (124IcG250)
Prostate Cancer Phase I/IILorene
(702)822-5282
A Phase I/II open-label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MCS110 in patients with prostate cancer and bone metastases
Prostate CancerPhase IIICarol
(702)822-5449
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
Prostate Cancer Phase IIIJacky
(702)822-5393
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
Clear Cell Renal Cell Carcinoma Phase ITherica
(702)822-5293
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1411 Administered Every 14 Days in Subjects with Advanced or Recurrent Clear Cell Renal Cell Carcinoma
Metastatic Renal Cell Cancer Phase IIIAnnette
(702)822-5177
Axitinib (AG-013736) as second line therapy for metastatic renal cell cancer: Axis Trial
Metastatic Clear Cell Carcinoma of the Kidney Phase IIAnnette
(702)822-5177
A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney
Non-Metastatic Hormone-Resistant Prostate Cancer Phase IIIJacky
(702)822-5393
A Phase III, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients.
Renal Cell
Carcinoma
 
Phase IIIAnnette
(702)822-5177
Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma.

Hematology

Chronic Lymphocytic Leukemia & Non-Hodgkin's Lymphoma Phase I/IIChristine
(702)822-5456
Multi-center, Open-label, Dose-escalating Phase I/II Trial of GS 9219 Administered Once Every Three Weeks Intravenously to Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma Phase IChristine
(702)822-5456
A Phase Ib Study of SGN-40 (anti-huCD40 mAb) in Combination with Rituximab and Gemcitabine for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Low Grade Recurrent B and T Cell LymphomaPhase IKaren
(702)822-5367
A Phase I Study of Intratumoral Poly-ICLC plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma

Lung

Non-Small Cell Lung Cancer Phase I/IIAnnette
(702)822-5177
Phase I/II Study of Pemetrexed (Alimta) plus Carboplatin, or Pemetrexed plus Cisplatin with Concurrent Radiation Therapy followed by Every 21-day Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage III A/B Non-Small Cell Lung Cancer
Non-Small-Cell Lung CancerPhase IIITherica
(702)822-5293
A randomized phase III comparison of standard-dose (60 Gy) versus high dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel in patients with stage IIIA/IIIB Non-Small Cell Lung Cancer
Lung Cancer Phase IIAnnette
(702)822-5177
A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol®/Paraplatin® (Paclitaxel/Carboplatin) Compared to Taxol®/Paraplatin® Alone in Previously Untreated Subjects with Lung Cancer
Non-Small Cell Lung Cancer Phase IIChristine
(702) 822-5456
Phase II study of a triplet combination of CBP501, pemetrexed and cisplatin as first line treatment in patients with locally advanced (stage IIIB with malignant pleural effusion or pericardial effusion) or metastatic (stage IV) non-squamous non small cell lung cancer (NSCLC)

Skin/Melanoma

Melanoma Phase IIAnnette
(702)822-5177
A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma
Melanoma Phase IIIAnnette
(702)822-5177
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORTC Melanoma Group

Phase IV


email
Contact Us
Please contact us with any questions or comments.
(702) 822-LIFE

(866) 621-NVCI

FightHere.org

Latest News

Nevada Cancer Institute Offers Free Webcast of Nevada National Kidney Cancer Patient, Survivor & Caregiver Conference

Read More

Miss USA Visits Nevada Cancer Institute

Read More

Nevada Cancer Institute and Siemens Foundation Announce 2009 Nursing & Healthcare Professional Scholarship Winners

Read More

Maps & Directions

To visit our state-of-the-art, flagship facility click here.

NVCI Bus Stop

Outreach & Education offices:

Las Vegas | Sparks | Elko | Fallon